Recent 8-K filings for DMII
Highest-materiality recent filing
DMIIU CEO Lynn Stockwell resigns after Sponsor fails to repay $566K overpayment; Roger Bendelac appointed CEO
- Lynn Stockwell resigned as CEO, Executive Chair, and Board member on Feb 28, 2026, after Board learned Sponsor could not repay $566,269 overpayment.
- Board accepted resignation and removed Stockwell from all positions effective Feb 28, 2026.
-
CFO Saleem Elmasri's monthly fee remains $3,500; equity grant increases from 100,000 to 175,000 shares earned at execution of definitive agreement.
-
DMIIU enters $1.4M convertible note agreement for de-SPAC financing; issues $300K interim note
Total financing commitment of $1.4M; $150K already received, $300K funded on March 30, 2026 as interim convertible note.
-
On March 11, 2026, Company issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office (Investor).
-
Lynn Stockwell resigned as CEO, Executive Chair, and Board member on Feb 28, 2026, after Board learned Sponsor could not repay $566,269 overpayment.
-
Drugs Made In America Acquisition II confirms trust account of ~$507.8M after sponsor irregularities
Sponsor made improper withdrawals from working capital between Sep 26, 2025 IPO and Dec 31, 2025.
-
Drugs Made In America Acquisition II Corp. appoints Saleem Elmasri as CFO after Glenn Worman resigns
Glenn Worman resigned as CFO and principal financial and accounting officer effective October 8, 2025, with no disagreement with the company.
-
Drugs Made In America Acquisition II closes $500M IPO and $12M private placement
IPO of 50M units at $10 each grossed $500M; units trade on Nasdaq (DMIIU).
-
SPAC Drugs Made In America Acquisition II Corp. closes $500M IPO; $500M in trust
Priced and closed IPO of 50M units at $10/unit for gross proceeds of $500M.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event other_material